FTC Order Slams POM Claims; Firm Vows Appeal
This article was originally published in The Tan Sheet
Executive Summary
The Federal Trade Commission’s 5-0 decision against POM Wonderful backs the ALJ’s cease-and-desist order and requires the firm to conduct at least two randomized controlled clinical trials for all disease-related claims going forward. POM vows to appeal the order in federal court.
You may also be interested in...
NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.
NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.
Certain Dri Antiperspirant Sweats It Out Against Big Players
With a thicker, “drip-free” reformulation of Certain Dri launching in January 2014, DSE Healthcare Solutions hopes its clinical-strength roll-on antiperspirant will appeal to more consumers with hyperhidrosis as well as those concerned about but not diagnosed with excessive perspiration.